We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KROS Rinvatercept: What to Know Before DMD Phase II Starts
Read MoreHide Full Article
Key Takeaways
Keros centers strategy on rinvatercept, advancing it into phase II for Duchenne muscular dystrophy.
KROS plans a Phase II DMD study start in Q2 2026 after securing orphan drug designation in 2025.
Phase I data showed muscle, fat, and bone benefits, supporting further studies in DMD and ALS.
Keros Therapeutics (KROS - Free Report) is tightening its focus around rinvatercept, a protein therapeutic designed to modulate transforming growth factor-beta family ligands tied to skeletal muscle, bone, and adipose biology. That narrower strategy puts upcoming clinical execution in Duchenne muscular dystrophy at the center of the story.
With an orphan drug designation secured and a phase II start planned next, the setup shifts from concept to calendar-driven catalysts.
KROS Pipeline Focus Shifts to Rinvatercept
Keros is positioning rinvatercept (KER-065) as its lead wholly owned program, with neuromuscular disorders as the priority lane. The company is advancing the asset first in Duchenne muscular dystrophy (DMD), then expanding to amyotrophic lateral sclerosis (ALS) as a follow-on indication.
The pivot is also enabled by a leaner internal spend profile after elritercept responsibilities and costs moved to Takeda under a licensing arrangement. That change lowers the research and development base and supports a more concentrated push behind rinvatercept’s next clinical steps.
Keros Sets Up DMD Readouts in 2026
The timeline is becoming more defined. In August 2025, the FDA granted orphan drug designation to rinvatercept for DMD.
Management plans to begin a phase II study in patients with DMD in the second quarter of 2026. That study start stands out as a near-term catalyst because it marks the program’s transition into patient-focused efficacy work in a high-need setting.
KROS Mechanism Targets Muscle, Fat, and Bone
Rinvatercept is engineered to selectively bind and inhibit transforming growth factor-beta pathway ligands, including myostatin (GDF8) and activin A. These ligands are described as key negative regulators of muscle and bone mass and strength.
By inhibiting these pathways, the intended outcomes include promoting skeletal muscle regeneration, increasing muscle size and strength, reducing body fat and muscle fibrosis, and enhancing overall bone strength. The mechanistic scope matters in DMD because functional decline is intertwined with progressive muscle weakness and broader metabolic and skeletal consequences.
Keros Highlights Steroid Trade-Offs in DMD Care
Keros frames glucocorticoids as the current standard of care in DMD while emphasizing the long-term trade-offs associated with chronic use. The company highlights side effects that include muscle catabolism, increased fat accumulation, and accelerated bone loss.
That positioning supports a rationale for approaches that aim to improve muscle and bone biology while also addressing body composition trends that can worsen over time in DMD care.
In a March 9 update, Keros shared new phase I data on rinvatercept that it said showed muscle, fat, and bone benefits. The candidate was reported to be well tolerated, with no serious adverse events.
The company also reported increases in muscle mass, reduced fat, and higher bone density. Management views these findings as reinforcing rinvatercept’s potential in both DMD and ALS, supporting the logic for moving forward with phase II studies.
Keros Maps ALS Next Steps After DMD Launch
Beyond DMD, Keros plans to engage with regulatory authorities in the second half of 2026 to discuss the design of a phase II study evaluating rinvatercept in patients with ALS.
This sequencing expands the program’s optionality. DMD provides the first major clinical proving ground, while ALS regulatory engagement introduces a second pathway to value creation if the mechanistic and biological signals translate in neuromuscular disease settings.
KROS Risks: Execution and Competitive DMD Arena
The strategy also concentrates risk. With the pipeline centered on rinvatercept, execution becomes the key swing factor for investor sentiment. Any timing slippage can push catalysts further out and heighten volatility while markets wait for clearer clinical read-throughs.
Competition is another structural headwind in DMD. The landscape includes established approaches and evolving dynamics. Sarepta Therapeutics (SRPT - Free Report) , rated Zacks Rank #3 (Hold), has a DMD franchise spanning exon-skipping therapies and an approved gene therapy that has faced recent distribution-related scrutiny. The space also includes corticosteroid use and branded options such as PTC Therapeutics’ (PTCT - Free Report) Emflaza, with PTC Therapeutics currently carrying a Zacks Rank #3 (Hold).
Against that backdrop, the rinvatercept story increasingly hinges on whether the phase II DMD start in the second quarter of 2026 stays on track and whether early biological signals ultimately translate into meaningful clinical benefit.
View the Zacks #1 Rank List
Image: Bigstock
KROS Rinvatercept: What to Know Before DMD Phase II Starts
Key Takeaways
Keros Therapeutics (KROS - Free Report) is tightening its focus around rinvatercept, a protein therapeutic designed to modulate transforming growth factor-beta family ligands tied to skeletal muscle, bone, and adipose biology. That narrower strategy puts upcoming clinical execution in Duchenne muscular dystrophy at the center of the story.
With an orphan drug designation secured and a phase II start planned next, the setup shifts from concept to calendar-driven catalysts.
KROS Pipeline Focus Shifts to Rinvatercept
Keros is positioning rinvatercept (KER-065) as its lead wholly owned program, with neuromuscular disorders as the priority lane. The company is advancing the asset first in Duchenne muscular dystrophy (DMD), then expanding to amyotrophic lateral sclerosis (ALS) as a follow-on indication.
The pivot is also enabled by a leaner internal spend profile after elritercept responsibilities and costs moved to Takeda under a licensing arrangement. That change lowers the research and development base and supports a more concentrated push behind rinvatercept’s next clinical steps.
Keros Sets Up DMD Readouts in 2026
The timeline is becoming more defined. In August 2025, the FDA granted orphan drug designation to rinvatercept for DMD.
Management plans to begin a phase II study in patients with DMD in the second quarter of 2026. That study start stands out as a near-term catalyst because it marks the program’s transition into patient-focused efficacy work in a high-need setting.
KROS Mechanism Targets Muscle, Fat, and Bone
Rinvatercept is engineered to selectively bind and inhibit transforming growth factor-beta pathway ligands, including myostatin (GDF8) and activin A. These ligands are described as key negative regulators of muscle and bone mass and strength.
By inhibiting these pathways, the intended outcomes include promoting skeletal muscle regeneration, increasing muscle size and strength, reducing body fat and muscle fibrosis, and enhancing overall bone strength. The mechanistic scope matters in DMD because functional decline is intertwined with progressive muscle weakness and broader metabolic and skeletal consequences.
Keros Highlights Steroid Trade-Offs in DMD Care
Keros frames glucocorticoids as the current standard of care in DMD while emphasizing the long-term trade-offs associated with chronic use. The company highlights side effects that include muscle catabolism, increased fat accumulation, and accelerated bone loss.
That positioning supports a rationale for approaches that aim to improve muscle and bone biology while also addressing body composition trends that can worsen over time in DMD care.
Keros Therapeutics, Inc. Price and Consensus
Keros Therapeutics, Inc. price-consensus-chart | Keros Therapeutics, Inc. Quote
KROS Phase I Data Adds Early Biological Support
In a March 9 update, Keros shared new phase I data on rinvatercept that it said showed muscle, fat, and bone benefits. The candidate was reported to be well tolerated, with no serious adverse events.
The company also reported increases in muscle mass, reduced fat, and higher bone density. Management views these findings as reinforcing rinvatercept’s potential in both DMD and ALS, supporting the logic for moving forward with phase II studies.
Keros Maps ALS Next Steps After DMD Launch
Beyond DMD, Keros plans to engage with regulatory authorities in the second half of 2026 to discuss the design of a phase II study evaluating rinvatercept in patients with ALS.
This sequencing expands the program’s optionality. DMD provides the first major clinical proving ground, while ALS regulatory engagement introduces a second pathway to value creation if the mechanistic and biological signals translate in neuromuscular disease settings.
KROS Risks: Execution and Competitive DMD Arena
The strategy also concentrates risk. With the pipeline centered on rinvatercept, execution becomes the key swing factor for investor sentiment. Any timing slippage can push catalysts further out and heighten volatility while markets wait for clearer clinical read-throughs.
Competition is another structural headwind in DMD. The landscape includes established approaches and evolving dynamics. Sarepta Therapeutics (SRPT - Free Report) , rated Zacks Rank #3 (Hold), has a DMD franchise spanning exon-skipping therapies and an approved gene therapy that has faced recent distribution-related scrutiny. The space also includes corticosteroid use and branded options such as PTC Therapeutics’ (PTCT - Free Report) Emflaza, with PTC Therapeutics currently carrying a Zacks Rank #3 (Hold).
Against that backdrop, the rinvatercept story increasingly hinges on whether the phase II DMD start in the second quarter of 2026 stays on track and whether early biological signals ultimately translate into meaningful clinical benefit.
KROS Zacks Rank
Keros currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.